Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Apple Restores Telegram to App Store After Content Policy Violation 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
HOUSTON, March 15, 2018 -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced that the Company will release its 2017 fourth quarter and full year financial results on Friday, March 23, 2018, before the U.S. financial markets open.
Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will host a conference call to discuss the results as follows:
| Date | Friday, March 23, 2018 | |||
| Time | 8:30 a.m. EDT | |||
| Toll free (U.S.) | (866) 394-2901 | |||
| International | (616) 548-5567 | |||
| Webcast (live and replay) | www.plxpharma.com under the ‘Investor Relations’ section. |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 8198566. The archived webcast will be available for 30 days via the aforementioned URL.
About Aspertec
Aspertec 325 mg is an FDA-approved aspirin product being developed to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric-coated aspirin, while also reducing the adverse gastric events common in an acute setting. PLx is focused on completing manufacturing scale-up and label finalization for Aspertec 325 mg aspirin dosage form and preparing an sNDA for Aspertec 81 mg maintenance dose form.
About PLx Pharma Inc.
PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide effective and safe aspirin products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients (API) to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce acute GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]
